Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S; Japan LCH Study Group (JLSG). Relapses of multisystem/multifocal bone Langerhans cell histiocytosis in paediatric patients: Data analysis from the JLSG-96/02 study. Br J Haematol. 2023; 200: 769-775.
Morimoto A, Shioda Y, Sakamoto K, Imamura T, Imashuku S; Japan LCH Study Group. Bone lesions of Langerhans cell histiocytosis triggered by trauma in children. Pediatr Int. 2022;64(1):e15199.
Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S; Japan LCH Study Group (JLSG). Long-term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96/02 studies. Br J Haematol. 2021;192(3):615-620.
Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S; Japan LCH Study Group (JLSG). Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies. Pediatr Blood Cancer. 2019;66(1):e27454.
Murakami I, Wada N, Nakashima J, Iguchi M, Toi M, Hashida Y, Higuchi T, Daibata M, Matsushita M, Iwasaki T, Kuwamoto S, Horie Y, Nagata K, Hayashi K, Oka T, Yoshino T, Imamura T, Morimoto A, Imashuku S, Gogusev J, Jaubert F. Merkel cell polyomavirus and Langerhans cell neoplasm. Cell Commun Signal. 2018;16(1):49.
Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, Goto H, Kosaka Y, Tsunematsu Y, Imashuku S; Japan LCH Study Group. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2018;108(2):192-198.
Morimoto A, Oh Y, Nakamura S, Shioda Y, Hayase T, Imamura T, Kudo K, Imashuku S; Japan Langerhans cell histiocytosis Study Group. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine. 2017;97:73-79.
Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, Yasui M, Koga Y, Kobayashi R, Ishii E, Fujimoto J, Horibe K, Bessho F, Tsunematsu Y, Imashuku S. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2016; 104(1): 99-109.
Imashuku S, Fujita N, Shioda Y, Noma H, Seto S, Minato T, Sakashita K, Ito N, Kobayashi R, Morimoto A. Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease. Int J Hematol. 2015; 101(2): 191-197.
Murakami I, Oh Y, Morimoto A, Sano H, Kanzaki S, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Nagata K, Hayashi K, Imashuku S, Gogusev J, Jaubert F, Oka T, Yoshino T. Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics. Clin Proteomics. 2015; 12(1): 16.
Murakami I, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Nagata K, Horie Y, Hayashi K, Imamura T, Morimoto A, Imashuku S, Gogusev J, Jaubert F, Takata K, Oka T, Yoshino T. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis. Cell Commun Signal. 2015; 13: 13.
Murakami I, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Horie Y, Hayashi K, Imamura T, Morimoto A, Imashuku S, Gogusev J, Jaubert F, Takata K, Oka T, Yoshino T. Detection of Merkel cell polyomavirus DNA sequences in peripheral blood and tissues from patients with Langerhans cell histiocytosis. Hum Pathol. 2014; 45(1): 119-126.
Oh Y, Morimoto A, Shioda Y, Imamura T, Kudo K, Imashuku S. High serum osteopontin levels in pediatric patients with high risk Langerhans cell histiocytosis. Cytokine. 2014; 70(2): 194-197.
Murakami I, Morimoto A, Oka T, Kuwamoto S, Kato M, Horie Y, Hayashi K, Gogusev J, Jaubert F, Imashuku S, Al-Kadar LA, Takata K, Yoshino T. IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy. Virchows Arch. 2013; 462(2): 219-228.
Morimoto A, Shimazaki C, Takahashi S, Yoshikawa K, Nishimura R, Wakita H, Kobayashi Y, Kanegane H, Tojo A, Imamura T, Imashuku S.Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Int J Hematol. 2013; 97(1): 103-108.
Shioda Y, Adachi S, Imashuku S, Kudo K, Imamura T, Morimoto A. Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan. Int J Hematol. 2011; 94(6): 545-551.
Imashuku S, Kudo N, Kaneda S, Kuroda H, Shiwa T, Hiraiwa T, Inagaki A, Morimoto A. Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis. Int J Hematol. 2011; 94(6): 556-560.
Murakami I, Oka T, Kuwamoto S, Kato M, Hayashi K, Gogusev J, Imamura T, Morimoto A, Imashuku S, Yoshino T. Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry. Virchows Arch. 2011; 459(2): 227-234.
Imashuku S, Shioda Y, Tsunematsu Y, Imamura T, Morimoto A. VCR/AraC chemotherapy and ND-CNS-LCH. Pediatr Blood Cancer. 2010; 55(1): 215-216.
Imashuku S, Kinugawa N, Matsuzaki A, Kitoh T, Ohki K, Shioda Y, Tsunematsu Y, Imamura T, Morimoto A. Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems. Int J Hematol. 2009; 90(4): 506-512.
Imashuku S. High dose immunoglobulin (IVIG) may reduce the incidence of Langerhans cell histiocytosis (LCH)-associated central nervous system involvement. CNS Neurol Disord Drug Targets. 2009; 8(5): 380-386.
Imashuku S, Shioda Y, Kobayashi R, Hosoi G, Fujino H, Seto S, Wakita H, Oka A, Okazaki N, Fujita N, Minato T, Koike K, Tsunematsu Y, Morimoto A; Japan LCH Study Group (JLSG). Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study Group. Haematologica 2008; 93(4): 615-618.
Morimoto A, Kobayashi R, Maeda M, Asami K, Bessho F, Imashuku S; Japan LCH Study Group. Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients. Pediatr Blood Cancer 2008; 50(4): 931-932.
Imashuku S, Okazaki NA, Nakayama M, Fujita N, Fukuyama T, Koike K, Minato T, Kobayashi R, Morimoto A; Japan LCH Study Group. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer 2008; 50(2): 308-311.
Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, Fujimoto J, Bessho F, Horibe K, Tsunematsu Y, Imashuku S; Japan Langerhans Cell Histiocytosis Study Group. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107(3):613-9.
Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;47(2):194-9.
Imashuku S, Ishida S, Koike K, Ichikawa M, Minato T, Suzuki Y, Kobayashi R, Morimoto A; Japan LCH Study Group. Cerebellar ataxia in pediatric patients with Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2004;26(11):735-9.
国際学会
Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S. Relapses in pediatric patients with multi-system or multi-focal bone Langerhans cell histiocytosis – data from the JLSG 96/02 study. 36th Annual Meeting of the Histiocyte Society Abstract, 2021
Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S, on behalf of the Japan LCH Study Group. CNS-permanent consequence in pediatric LCH patients treated by an Ara-C containing regimen: the data from JLSG-96/02 studies in Japan. 35th Annual Meeting of the Histiocyte Society Abstract, 2019
Morimoto A, Shioda Y, Sakamoto K, Imashuku S. Analysis of bone LCH cases triggered by bruising; result from JLSG-02 study. 35th Annual Meeting of the Histiocyte Society Abstract, 2019
Morimoto A, Shioda Y, Imamura T, Kudo K, Tsunematsu Y, Imashuku S, on behalf of the Japan LCH Study Group. Combination of routine laboratory examination at diagnosis can eztract extremely poor prognostic group in pediatric Langerhans cell histiocytosis with high accuracy. 34th Annual Meeting of the Histiocyte Society Abstract, 2018
Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S, on behalf of the Japan LCH Study Group (JLSG). Neurodegenerative CNS disease in pediatric Langerhans cell histiocytosis (LCH): identified during long term follow-up in the JLSG 96/02 study. 34th Annual Meeting of the Histiocyte Society Abstract, 2018
Shioda Y, Morimoto A, Imamura T, Kudo K, Tsunematsu Y, Imashuku S, on behalf of the Japan LCH Study Group. Prognostic significance of the combination of liver involvement, spleen involvement and younger age at diagnosis in the pediatric Langerhans cell histiocytosis. 34th Annual Meeting of the Histiocyte Society Abstract, 2018
Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, Goto H, Kosaka Y, Tsunematsu Y, Imashuku S, on behalf of the Japan LCH Study Group. C-reactive protein and bone pain at diagnosis predict the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal lesions: result of The Japan Langerhans Cell Histiocytosis Study Group-02 protocol study. 33rd Annual Meeting of the Histiocyte Society Abstract, 2017
Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S. Risk factors for diabetes insipidus in pediatric patients with Langerhans cell histiocytosis treated with cytarabine-based chemotherapy; the results of JLSG-96/02 study. 33rd Annual Meeting of the Histiocyte Society Abstract, 2017
Morimoto A, Shioda Y, Imamura T, Tsunematsu Y, Imashuku S. The association between organ involvements and survival in children with Langerhans cell histiocytosis; the results of JLSG-96/02 study. 32th Annual Meeting of the Histiocyte Society Abstract, 2016
Morimoto A, Shioda Y, Imamura T, Kudo K, Ishii E, Horibe K, Bessho F, Tsunematsu Y, Imashuku S. Intensified and prolonged therapy did not improve the outcome in Langerhans cell histiocytosis with single-system multifocal bone lesions: result of JLSG-02 protocol study. 31th Annual Meeting of the Histiocyte Society Abstract, 2015
Shioda Y, Tanaka R, Fujita N, Noma H, Seto S, Minato T, Sakashita K, Ito N, Kobayashi R, Imamura T, Morimoto A, Imashuku S. Long-term (⟩3 years) IVIG treatment in an attempt to prevent the progression of CNS neurodegenerative disease in patients with LCH. 31th Annual Meeting of the Histiocyte Society Abstract, 2015
Morimoto A, Oh Y, Shioda Y, Imamura T, Kudo K, Imashuku S. Analysis of serum osteopontin levels in pediatric patients with Langerhans cell histiocytosis. 29th Annual Meeting of the Histiocyte Society Abstract, 2013
Shioda Y, Morimoto A, Imamura T, Kudo K, Imashuku S. Analysis of permanent consequences in pediatric patients with Langerhans cell histiocytosis: data of the JLSG-96 and JLSG-02 studies in Japan. 29th Annual Meeting of the Histiocyte Society Abstract, 2013
Morimoto A, Shioda Y, Imamura T, Kudo K, Sato T, Shiohara M, Yasui M, Koga Y, Kobayashi R, Ishii E, Fujimoto J, Horibe K, Bessho F, Tsunematsu Y, Imashuku S, Japan LCH Study Group. Intensified and prolonged therapy improved the outcome in multi-system Langerhans cell histiocytosis. 28th Annual Meeting of the Histiocyte Society Abstract, 2012
Oh Y, Morimoto A, Itoh T, Masuzawa A, Kashii Y, Gunji Y Momoi MY. A case of myelodysplastic syndrome after 2-chlorodeoxyadenosine therapy for recurrent Langerhans cell histiocytosis. 28th Annual Meeting of the Histiocyte Society Abstract, 2012
Morimoto A, Shimazaki C, Takahashi S, Yoshikawa K, Kuroda R, Wakiya H, Kobayashi H, Kanegane H, Akiyama S, Tojyo A, Imamura T, Imashuku S. Multifocal LCH in adult patients treated with special C regimen of JLSG-02 protocol. 27th Annual Meeting of the Histiocyte Society Abstract, 2011
Murakami I, Oka T, Hayashi K, Gogusev J, Jaubert F, Morimoto A, Imashuku S, Yoshino T. Gene expression profiling of PTPN6 (SHP-1) transfected Langerhans cell-line (ELD-1)-compared with open data of LCH subtype (GSE16395). 27th Annual Meeting of the Histiocyte Society Abstract, 2011
Kudo K, Morimoto A, Imamura T, Shioda Y, Sato T, Ishii E, Horibe K, Kinugawa N, Tsunematsu Y, Imashuku S. Outcome of poor responders at 6 weeks of induction therapy: JLSG-02 protocol study for multisystem Langerhans cell histiocytosis in Japan. 26th Annual Meeting of the Histiocyte Society Abstract, 2010
Morimoto A, Nakamura S, Shioda Y, Imamura T, Oh Y, Imashuku S, Momoi M. Comprehensive analysis of serum cytokine/chemokine and growth factors in pediatric patients with Langerhans cell histiocytosis. 26th Annual Meeting of the Histiocyte Society Abstract, 2010
Adachi S, Hayashi A, Hamada H, Kizaki Z, Ono S, Morimoto A. A case of pulmonary LCH with recurrent life-threatning pneumothorax treated with prednisolone and 6-mercaptopurine. 25th Annual Meeting of the Histiocyte Society Abstract, 2009
Murakami I, Oka T, Sato H, Morito T, Takata K, Shinno Y, Takano M, Washio K, Ko S, Tamura M, Ohnishi N, Ichimura K, Sato Y, Yanai H, Ohara N, Kondo E, Takahashi K, Tanaka T, Gogusev J, Jaubert F, Morimoto A, Imashuku S, Akagi T, Yoshino T. Immunohistchemical analysis of PTPN6 (SHP1) on Langerhans cell histiocytosis. 24th Annual Meeting of the Histiocyte Society Abstract, 2008
Shioda Y, Morimoto A, Ueyama J, Shimada H, Fujimoto J, Tsunematsu Y, Imashuku S. Langerhans cell histiocytosis involving the thyroid associated with cervical soft tissue mass in children: report of three cases. 24th Annual Meeting of the Histiocyte Society Abstract, 2008
Nakatani T, Morimoto A, Shioda Y, Yasui M, Hasegawa D, Hyakuna N, Watanabe N, Kawakami K, Ishii E, Okimoto Y, Kudo H, Asami K, Kohdera U, Kinugawa N, Maeda M, Imashuku S. Reappraisal of classical biological markers at the diagnosis of Langerhans cell histiocytosis. 23rd Annual Meeting of the Histiocyte Society Abstract, 2007
Morimoto A, Sato T, Kobayashi R, Kamizono J, Kanegane H, Ohga S, Suzuki N, Ishii E, Fujimoto J, Wakiguchi H, Horibe K, Mizutami S, Mugishima H, Bessho F, Tsunematu Y, Imashuku S. Therapeutic result of JLSG-02 protocol study for multi-system Langerhans cell histiocytosis (LCH) patients: interim report. 23rd Annual Meeting of the Histiocyte Society Abstract, 2007
Imashuku S, Shioda Y, Kobayashi R, Koike K, Minato T, Okazaki N, Fujita N, Hosoi G, Fujimo T, Seto S, Wakita H, Oka A, Tsunematsu Y, Morimoto A and the Japan LCH Study Group (JLSG). Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis: JLSG report. 23rd Annual Meeting of the Histiocyte Society Abstract, 2007.
